Mesothelioma
Findings from Emory University in mesothelioma reported
Published in Cancer Weekly, February 17th, 2009
"We conducted a phase II study of belinostat in patients with relapsed malignant pleural mesothelioma. Patients with advanced mesothelioma, progression with one prior chemotherapy regimen and Eastern Cooperative Oncology Group performance status 0-2 were eligible. Belinostat was administered at 1000 mg/m(2) intravenously over 30 Minutes oil days 1-5 of every 3 week cycle. The primary end point was response rate. The Simon two-stage design was used. Disease...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2009-02-17)
More Articles from Cancer Weekly
- Adventrx Pharmaceuticals, Inc.
ADVENTRX Completes Patient Enrollment in ANX-514 Bioequivalence Study - Array BioPharma Inc.
Array BioPharma Reports Financial Results for the Second Quarter of Fiscal 2009 - Bioengineering
Findings in bioengineering reported from A. Ambade and co-researchers - Cancer Gene Therapy
Findings in cancer gene therapy reported from M. Takanashi and co-researchers - Cancer Gene Therapy
New cancer gene therapy research from Fourth Military Medical University described - Cancer Gene Therapy
New cancer gene therapy research from W.F. Shi and colleagues discussed - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
